

GLOBAL ACADEMY *of* **WOMEN'S CANCER**

**EUROPEAN
HYBRID MEETING**

Simply the Best Education
you can get

**5/6 JULY
2024**
**MUNICH
GERMANY**

PRELIMINARY PROGRAMME

Updated 06.03.2024

global-academy-of-womens-cancer.org

CONTENT

Welcome Message	1
Programme at a Glance	2–3
Programme Friday, July 5 th	4–9
Programme Saturday, July 6 th	10–15
Satellite Symposia Overview	16–17
Executive Board	18
Invited Faculty	19–20
Floor Plan	21
Call for Abstracts	22–24
General Information	25
Sponsors	27

The Global Academy of Women's Cancer – European Hybrid Meeting 2024
is supported by



Berufsverband Niedergelassener und
ambulant tätiger Gynäkologischer Onkologen
in Deutschland e.V.



Dear Colleagues and Friends,

Dear Colleagues and Friends,

Following 3 successful international meetings, we are looking forward to returning to Munich with the 4th edition of the GAWC!

In 2024, the Global Academy of Women's Cancer will meet for its 4th International Meeting on July 5/6 in Munich, Germany.

We invite you to attend keynote lectures, debates, Speakers Corner, Meet the Professor sessions, multidisciplinary panel discussions, case discussions, and sessions on the hot topics. During the 1.5-day meeting in Munich, the latest results and treatment strategies will be summarized, discussed and presented by international experts. The interactive congress offers a comprehensive overview of all new developments in breast and gynaecological cancers, which account for 50% of all cancers in women, as well as direct exchange with the world's leading experts in these fields. The aim is to present the latest scientific findings in practical recommendations for everyday clinical practice.

We would like to invite you to actively participate in the event!

Join us and exchange ideas with your colleagues and experts from all over the world, broaden your knowledge and take away ideas and recommendations for your daily work.

We look forward to welcoming you in Munich!

Andreas du Bois, MD
Scientific Chair

Jonathan Ledermann, MD
Scientific Chair

Sherko Kümmel, MD
Scientific Chair

Peter Schmid, MD
Scientific Chair

Nadia Harbeck, MD
Local Scientific Chair

Sven Mahner, MD
Local Scientific Chair

Philipp Harter, MD
Local Scientific Chair

PROGRAMME AT A GLANCE


Friday, July 5th

8:00		
9:00		
10:00	9:30–10:10 MEET THE EXPERTS SESSIONS Interactive sessions before the event	
	OPENING OF THE CONFERENCE	
	JOINT LECTURE I	
11:00	SATELLITE SYMPOSIUM I GOLD	
12:00	SATELLITE SYMPOSIUM II	
	LUNCH BREAK	
13:00	GYNAE-ONCOLOGY SESSION I	BREAST CANCER SESSION I
14:00		
15:00		
	BREAK	
16:00	SATELLITE SYMPOSIUM III PLATINUM	
	JOINT LECTURE II	
17:00		
	SATELLITE SYMPOSIUM IV GOLD	
18:00		
19:00	GYNAE-ONCOLOGY SESSION II	BREAST CANCER SESSION II
20:00		

PROGRAMME AT A GLANCE

Saturday, July 6th

8:00	8:00–8:40 MEET THE EXPERTS SESSIONS Interactive sessions before the event	
9:00	GYNAE-ONCOLOGY SESSION III	BREAST CANCER SESSION III
10:00	COFFEE BREAK	
11:00	SATELLITE SYMPOSIUM V GOLD	
	SATELLITE SYMPOSIUM VI	
12:00	ORAL COMMUNICATION	
	SATELLITE SYMPOSIUM VII GOLD	
13:00	LUNCH BREAK	
14:00	GYNAE-ONCOLOGY SESSION IV	BREAST CANCER SESSION IV
15:00		
16:00	JOINT LECTURE IV	
17:00	CLOSING REMARKS AND FAREWELL	
18:00		
19:00		
20:00		



PROGRAMME

Friday, July 5th

09:00–10:10

Room

MEET THE EXPERTS SESSIONS

Treatment of Recurrent endometrial cancer after IO

Nicoletta Colombo, Milan, Italy

Mansoor Raza Mirza, Copenhagen, Denmark

Primary or interval debulking. How to select the right strategy.

Christina Fotopoulou, London, United Kingdom

Andreas du Bois, Essen, Germany

How to treat non-HRD patients who had neither PD nor response after 1st line TC?

Antonio González-Martin, Madrid, Spain

Jonathan Ledermann, London, United Kingdom

09:00–10:10

Room

MEET THE EXPERTS SESSIONS

Management of immune-related adverse events

Peter Schmid, London, United Kingdom

Melissa Phillips, London, United Kingdom

Current topic and standards in breast surgery after neoadjuvant therapy

Jens-Uwe Blohmer, Berlin, Germany

Stefan Paepke, Munich, Germany

Management of endocrine related side effects

Rachel Würstlein, Munich, Germany

Petra Voiß, Essen, Germany

10:15–10:20

Room

WELCOME AND OPENING

Andreas du Bois, Essen, Germany

Sven Mahner, Munich, Germany

Sherko Kümmel, Essen, Germany

Nadia Harbeck, Munich, Germany

Friday, July 5th

10:20–11:00

JOINT LECTURE 1**My Personal Highlights 2024**CHAIRS: NADIA HARBECK, MUNICH, GERMANY
NN10:20–10:40 ... in Breast Cancer
Hope S. Rugo, California, USA11:40–11:00 ... in Gynaecological Oncology
Antonio González-Martin, Madrid, Spain

11:00–12:00

Room

SATELLITE SYMPOSIUM I
GOLD

12:00–12:30

Room

SATELLITE SYMPOSIUM II

12:30–13:10

Room

LUNCH BREAK



Friday, July 5th

13:10–15:10

Room

GYNAE-ONCOLOGY SESSION I

FIGO IV Ovarian Cancer

CHAIR: ANDREAS DU BOIS, ESSEN, GERMANY

MODERATED INTERACTIVE CASE DISCUSSION 1:

13:10–14:10 Which type of FIGO IV should receive NACT?

Giovanni Aletti, Milan, Italy

What to do if only a minor Response is achieved after 3 courses?

Oliver Zivanovic, Heidelberg, Germany

What to do if only NC has been achieved after 6 courses?

Christina Fotopoulou, London, United Kingdom

LECTURES

CHAIRS: ANTONIO GONZÁLEZ-MARTIN, MADRID, SPAIN

PHILIPP HARTER, ESSEN, GERMANY

14:10–14:30 Keynote Lecture 1: OC – Life after PARPi

Frederik Marmé, Mannheim, Germany

OXFORD DEBATE 1

CHAIRS: OLIVER ZIVANOVIC, HEIDELBERG, GERMANY

PHILIPPE MORICE, VILLEJUIF, FRANCE

14:30–15:10 LNE still necessary in ovarian cancer FIGO I/II?

Pro: **Sven Mahner, Munich, Germany**

Contra: **Nicoletta Colombo, Milan, Italy**

Friday, July 5th

13:10–15:10

Room

BREAST SESSION 1

HR +/- Early Breast Cancer

CHAIRS: NADIA HARBECK, MUNICH, GERMANY
MICHAEL GNANT, VIENNA, AUSTRIA**LECTURES**

- 13:10–13:25 Keynote Lecture 1 a: EBC: HR+: Who should receive (neo)adjuvant chemotherapy +/- Immunotherapy for HR+ Breast Cancer and how?
Sherko Kümmel, Essen, Germany
- 13:25–13:40 Keynote Lecture 1 b: EBC: HR+: Adjuvant CDK4/6i: For who, how long, what agent?
Nadia Harbeck, Munich, Germany
- 13:40–13:55 Keynote Lecture 2: EBC: HR+: Optimal duration and type of endocrine therapy in pre and post-menopausal women
Michael Gnant, Vienna, Austria

MODERATED INTERACTIVE CASE DISCUSSIONCHAIRS: WOLFGANG JANNI, ULM, GERMANY
NADIA HARBECK, MUNICH, GERMANY
MICHAEL GNANT, VIENNA, AUSTRIA

- 14:00–14:10 Stage II, N0 – adjuvant Ribociclib?
- 14:10–14:20 Premenopausal – Stage II, pN1 – Chemotherapy or only Ovarian Suppression?
- 14:20–14:30 Premenopausal prior – Postmenopausal after adjuvant chemotherapy – what is the optimal endocrine therapy?
- 14:30–14:40 BRCA pos. and indication for chemotherapy – Carboplatin yes or no?
- 14:40–14:50 Extended adjuvant therapy after 5 years of AI and GnRH – what is the best option?
- 14:50–15:10 Panel Discussion:
Wolfgang Janni, Nadia Harbeck, Michael Gnant, Hope S. Rugo, Nadia Harbeck, Sherko Kümmel, Giuseppe Curigliano, Peter Schmid, Aditya Bardia

15:10–15:25

BREAK

PROGRAMME

Friday, July 5th

15:25–16:25

Room

SATELLITE SYMPOSIUM III PLATINUM

16:25–17:25

Room

JOINT LECTURE 2

CHAIRS: JAVIER CORTES, BARCELONA, SPAIN
ANTONIO GONZÁLEZ-MARTIN, MADRID, SPAIN
PHILIPP HARTER, ESSEN, GERMANY

LECTURES

- 16:25–16:45 Keynote Lecture 3: From taking personalized medicine to the clinics: barriers and how to overcome them
Jonathan Ledermann, London, United Kingdom
- 16:45–17:05 Special Lecture 1: Management of hereditary Breast Cancer
Shani Paluch-Shimon, Jerusalem, Israel
- 17:05–17:25 Special Lecture 2: Role of liquid biopsy in treatment selection of Early and Metastatic Breast Cancer
Antonio Llombart-Cussac, Valencia, Spain (invited)

17:25–18:10

Room

SATELLITE SYMPOSIUM IV GOLD

18:10–19:10

GYNAE-ONCOLOGY SESSION II

CHAIRS: MANSOOR RAZA MIRZA, COPENHAGEN, DENMARK
NICOLETTA COLOMBO, MILAN, ITALY

ADC IN GYNAECOLOGICAL ONCOLOGY

- 18:10–18:30 Folate receptor alpha in GO
Antonio González-Martin, Madrid, Spain
- 18:30–18:50 Other targets in GO
Christian Marth, Innsbruck, Austria
- 18:50–19:10 Management of ADC toxicity
Nicole Concin, Innsbruck, Austria

Friday, July 5th

18:10–19:30

Room

BREAST SESSION II**HR+ Metastatic Breast Cancer**

CHAIRS: ADITYA BARDIA, BOSTON, USA
 PETER SCHMID, LONDON, UNITED KINGDOM

LECTURES

- 18:10–18:25 State of the Art Lecture 1: Optimal treatment strategy in 1st line after (neo)adjuvant CDK4/6 Inhibitors or Chemo-Immune-Therapy
Aditya Bardia, Boston, USA
- 18:25–18:40 State of the Art Lecture 2: Optimal setting of endocrine therapy after CDK4/6 Inhibition at 1st line
Giuseppe Curigliano, Milan, Italy
- 18:40–18:55 State of the Art Lecture: Optimal setting and sequencing of ADC's
Hope S. Rugo, California, USA

MODERATED INTERACTIVE CASE DISCUSSIONS

CHAIRS: CHRISTIAN JACKISCH, ESSEN, GERMANY
 ADITYA BARDIA, BOSTON, USA

- 18:55–19:05 1. Adj. CDK4/6i. – 2yrs. later HR + MBC with liver mets – Re-Induction of CDK4/6i?
- 19:05–19:15 2. 1st line CDK4/6i. – fast relapse and ESR1mt. + PI3Kmt. – which therapy?
- 19:15–19:25 Panel Discussion:
Aditya Bardia, Giuseppe Curigliano, Hope S. Rugo, Peter Schmid, Javier Cortes, Nadia Harbeck, Christian Jackisch
- 19:25–19:30 Summary Day 1
 HR +: My take home message on one slide
Peter Schmid, London, United Kingdom



Saturday, July 6th

08:00–08:40

Room

MEET THE EXPERTS SESSIONS

Wire, Clips, Localizer – Best option for marking the tumor and lymph node

Marc Thill, Frankfurt, Germany

Mattea Reinisch, Essen, Germany

New treatment paradigms in HER 2 low disease

Giuseppe Curigliano, Milan, Italy

Christian Jackisch, Essen, Germany

Best management of effects of ADC's

Hope S. Rugo, California, USA

Rupert Bartsch, Vienna, Austria

Herausforderung Therapieadhärenz – Klinik meets Praxis (German Session)

Jörg Schilling, Berlin, Germany

Jens-Uwe Blohmer, Berlin, Germany

08:40–10:25

Room

GYNAE-ONCOLOGY SESSION III

OXFORD DEBATE 2

CHAIRS: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM

CHRISTINA FOTOPOULOU, LONDON, UNITED KINGDOM

08:40–09:25 Is Immunotherapy ready for 1st line treatment of ovarian cancer?

Pro: Philipp Harter, Essen, Germany

Contra: Frederik Marmé, Mannheim, Germany

CASE DISCUSSION 3

LOCALLY ADVANCED CERVICAL CANCER

CHAIR: NICOLETTA COLOMBO, MILAN, ITALY

09:25–09:45 Surgical LN Staging?

Sven Mahner, Munich, Germany

09:45–10:05 Role of NACT?

Jonathan Ledermann, London, United Kingdom

10:05–10:25 Any role for surgery?

Viola Heinzemann, Basel, Switzerland

Saturday, July 6th

08:40–10:30

Room

BREAST SESSION III

CHAIRS: SARA A. HURVITZ, WASHINGTON, USA
ALESSANDRA GENNARI, NOVARA, ITALY

DEBATE 1

08:40–09:10 When to escalate in the adjuvant or postneoadjuvant setting?

Sara A. Hurvitz, Washington, USA

When to de-escalate in the adjuvant or postneoadjuvant setting?

Nadia Harbeck, Munich, Germany

LECTURES

09:10–09:30 Keynote Lecture 4: MBC: Her2 Overexpression Optimal Sequencing of current treatment options

Javier Cortes, Madrid, Spain

MODERATED INTERACTIVE CASE DISCUSSIONS

CHAIRS: ALESSANDRA GENNARI, NOVARA, ITALY
MARC THILL, FRANKFURT, GERMANY
RUPERT BARTSCH, VIENNA, AUSTRIA

09:30–09:40 NonpCR after 12 weeks NACT – EC followed by T-DM1 or only T-DM1?

09:40–09:50 Large DCIS with palpable mass – Re-Biopsy or Surgery?

09:50–10:00 Screening of Brain Mets if asymptomatic?

10:00–10:10 Fertility in Her2, TNBC, HR+ – different treatment options

10:10–10:30 Panel Discussion:

Nadia Harbeck, Javier Cortes, Hope S. Rugo, Giuseppe Curigliano, Sherko Kümmel,

Alessandra Gennari, Marc Thill, Rupert Bartsch, Sara A. Hurvitz

10:30–10:45

COFFEE BREAK

PROGRAMME

Saturday, July 6th

10:45–11:30

Room

SATELLITE SYMPOSIUM V
GOLD

11:30–12:00

SATELLITE SYMPOSIUM VI

12:00–12:20

Room

ORAL COMMUNICATION

CHAIRS: WOLFGANG JANNI, ULM, GERMANY
HOPE S. RUGO, CALIFORNIA, USA

12:00–12:04 Oral Communication 1

12:04–12:08 Oral Communication 2

12:08–12:12 Oral Communication 3

12:12–12:20 Poster Award Ceremony

12:20–13:05

Room

SATELLITE SYMPOSIUM VII
GOLD

13:05–13:50

Room

LUNCH BREAK

Saturday, July 6th

13:50–15:50

Room

GYNAE-ONCOLOGY SESSION IV**LECTURES**

CHAIRS: ANTONIO GONZÁLEZ-MARTIN, MADRID, SPAIN
 PHILIPP HARTER, ESSEN, GERMANY

13:50–14:10 **Keynote Lecture 2: SoA: Low-grade serious OC**
David SP Tan, Singapore

OXFORD DEBATE 3

CHAIRS: CHRISTIAN MARTH, INNSBRUCK, AUSTRIA
 DAVID SP TAN, SINGAPORE

14:10–14:50 **EC FIGO III: Do we still need chemotherapy in 1st line?**

14:10–14:30: Pro: **Viola Heinzlmann, Basel, Switzerland**

14:30–14:50: Contra: **Mansoor Raza Mirza, Copenhagen, Denmark**

1ST LINE ENDOMETRIAL CANCER

CHAIR: MANSOOR RAZA MIRZA, COPENHAGEN, DENMARK

MODERATED INTERACTIVE CASE DISCUSSION 2

14:50–15:10 **Timing of testing for molecular analysis**
Christian Marth, Innsbruck, Austria

15:10–15:30 **Can we omit chemotherapy**
Mansoor Raza Mirza, Copenhagen, Denmark

15:30–15:50 **Who are the patients benefiting in pMMR group?**
Mansoor Raza Mirza, Copenhagen, Denmark



Saturday, July 6th

13:50–15:50

Room

BREAST SESSION IV

CHAIRS: SHANI PALUCH-SHIMON, JERUSALEM, ISRAEL
REBECCA DENT, SINGAPORE

LECTURES

13:50–14:05 Keyote Lecture: EBC – TNBC Update on treatment of early TNBC
Peter Schmid, London, United Kingdom

DEBATE 2

14:05–14:35 Should we escalate in case of residual disease
Giuseppe Curigliano, Milan, Italy

Should we de-escalate in case of residual disease
Javier Cortes, Madrid, Spain

LECTURES

14:35–14:50 Keynote Lecture 5: MBC: TNBC – Optimal Sequencing of current treatment options
Rebecca Dent, Singapore

CASE AND PANEL DISCUSSION 3

CHAIRS: REBECCA DENT, SINGAPORE
OLEG GLUZ, MONCHENGLADBACH, GERMANY
MICHAEL BRAUN, MUNICH, GERMANY

14:50–15:00 Postneoadjuvant – BRCA pos. or neg. – best treatment options?

15:00–15:10 Stage IIa – after 12 weeks cCR – a) pcR, b) RCB 1 – best treatment options?

15:10–15:20 MBC-OMD – bone only TNBC – best treatment options?

15:20–15:30 MBC-OMD – CIT (bone, liver) – 1 new bone lesion – Liver SD-best treatment options?

15:30–15:40 Panel Discussion:
Rebecca Dent, Oleg Gluz, Michael Braun, Peter Schmid, Javier Cortes, Shani Paluch-Shimon, Antonio Llombart, Giuseppe Curigliano

15:50–15:55 Summary Day 2
Her2 and TNBC: My take home message on two slides

Saturday, July 6th

15:55–17:15

Room

JOINT LECTURE 4

Special tutorial: How to design a study, and how to read a paper:
Pitfalls, shortcomings and misinterpretations

CHAIRS: ANDREAS DU BOIS, ESSEN, GERMANY
MANSOOR RAZA MIRZA, COPENHAGEN, DENMARK

15:55–16:20 New designs for phase III clinical trials and how they achieve
better answers more quickly
Max Parmar, London, United Kingdom

16:20–16:45 Piece by piece: OVHIPEC-1, N Engl J Med 2028
Oliver Zivanovic, Heidelberg, Germany
Philipp Harter, Essen, Germany

16:45–17:10 Piece by piece: GOG 213 and DESKTOP, N Engl J Med 2019 & 2021
Christina Fotopoulou, London, United Kingdom
Giovanni Aletti, Milan, Italy

17:15

FAREWELL

SATELLITE SYMPOSIA OVERVIEW

Friday, July 5th

11:00–12:00	SATELLITE SYMPOSIUM I GSK
12:00–12:30	SATELLITE SYMPOSIUM II Stemline
15:25–16:25	SATELLITE SYMPOSIUM III ImmunoGen
17:25–18:10	SATELLITE SYMPOSIUM IV Novartis

Saturday, July 6th

- 10:45–11:30 SATELLITE SYMPOSIUM V
MSD
- 11:30–12:00 SATELLITE SYMPOSIUM VI
Gilead
- 12:20–13:05 SATELLITE SYMPOSIUM VII
AstraZeneca



Initiators of the Global Academy of Women's Cancer

Andreas du Bois, MD
Essen, Germany

Jonathan Ledermann, MD
London, United Kingdom

Sherko Kümmel, MD
Essen, Germany

Peter Schmid, MD
London, United Kingdom

Scientific Board Gynaecological Oncology

Nicoletta Colombo, MD
Milan, Italy

Mansoor Raza Mirza, MD
Copenhagen, Denmark

Christina Fotopoulou, MD
London, United Kingdom

David SP Tan, MD
Singapore

**Antonio González-
Martin, MD**
Madrid, Spain

Scientific Board Breast Cancer

Carlos Barrios, MD
Rio de Janeiro, Brazil

Rebecca Dent, MD
Singapore

Javier Cortes, MD
Barcelona, Spain

Nadia Harbeck, MD
Munich, Germany

Giuseppe Curigliano, MD
Milan, Italy

Hope S. Rugo, MD
San Francisco, USA

Giovanni Aletti, MD

IEO – Istituto Europeo di Oncologia
Via Ripamonti, 435
20141 Milan, Italy

Aditya Bardia, MD

Mass General Cancer Center:
Hematology Oncology
55 Fruit St.
Boston, MA 02114, USA

Rupert Bartsch, MD

Clinical Research Unit
Clinical Department of Oncology
Department of Internal Medicine I,
Medical University of Vienna
Währinger Gürtel 18–20
1090 Vienna, Austria

Jens Blohmer, MD

Campus Charité Mitte
Charitéplatz 1
10117 Berlin, Germany

Michael Braun, MD

Rotkreuzklinikum München
Frauenklinik
Taxisstraße 3
80637 Munich, Germany

Nicoletta Colombo, MD

Divisione di Ginecologia
Oncologia Medica
IRCCS Istituto Europeo di Oncologia
Via Ripamonti 435
20144 Milan, Italy

Nicole Concin, MD

Essen-Mitte Evangelical Hospitals,
Huysens Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Essen, Germany
University of Innsbruck
Innsbruck, Austria

Javier Cortes, MD

Vall d'Hebron Institute of
Oncology, Centro Cellex
Carrer de Natzaret, 115–117
08035 Barcelona, Spain

Giuseppe Curigliano, MD

University of Milan
Via Ripamonti, 435 – IEO – Istituto
Europeo di Oncologia
20141 Milan, Italy Milan Italy

Rebecca Dent, MD

National Cancer Center Singapore
11 Hospital Cres
Singapore 169610 Singapore

Andreas du Bois, MD

Essen-Mitte Evangelical Hospitals
Huysens Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

Christina Fotopoulou, MD

Imperial College London
Hammersmith Hospital
Du Cane Road, W12 7BH
London, United Kingdom

Alessandra Gennari, MD

Maggiore Hospital Novara
Corso Mazzini n. 18
28100 Novara, Italy

Oleg Gluz, MD

Breast Center Niederrhein
Ludwig-Weber-Straße 15
41061 Mönchengladbach
Germany

Michael Gnant, MD

Medical University of Vienna
Breast Health Center
Währinger Guertel 18–20
1090 Vienna, Austria

Antonio González-Martin, MD

Servicio de Oncologia Medica
Clinica Universidad de Navarra
Avenida P o XII, 36
31008 Madrid, Spain

Nadia Harbeck, MD

Women's clinics Großhadern
and Maistrasse-Innenstadt
Breast Center of the
University of Munich
Marchioninstr. 15
81377 Munich, Germany

Philipp Harter, MD

Essen-Mitte Evangelical Hospitals,
Huysens Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

Viola Heinzlmann, MD

University Hospital Basel
Department of Clinical Research
University of Basel c/o University
Hospital Basel
Spitalstrasse 8/12
new building 2nd floor
CH-4031 Basel, Switzerland

Christian Jackisch, MD

Essen-Mitte Evangelical Hospitals
Huysens Foundation
Essen-Huttrop
Henricistr. 92
45136 Essen, Germany

Wolfgang Janni, MD

Ulm University Hospital
Prittwitzstr. 43
89075 Ulm, Germany

Sherko Kümmel, MD

Essen-Mitte Evangelical Hospitals
Huysens Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

Jonathan Ledermann, MD

Clinical Director
UCL Cancer Institute
Department of Oncology
72 Huntley Street
London WC1E 6DD
United Kingdom London United
Kingdom

Antonio Llombart-Cussac, MD

Medical Oncology Department,
Hospital Arnau de Vilanova,
San Clemente, 12
46015 Valencia, Spain



INVITED FACULTY

Sven Mahner, MD

LMU Hospital, Clinic and Polyclinic
for Obstetrics
and Gynecology, Campus Großhadern
and City Center – Maistrasse
Marchioninstr. 15
81377 Munich, Germany

Frederik Marmé, MD

University Medical Center Mannheim
Theodor-Kutzer-Ufer 1–3
68167 Mannheim, Germany

Christian Marth, MD

Medical University of Innsbruck,
University Clinic for Gynecology and
Obstetrics
Anichstr. 35
6020 Innsbruck, Austria

Mansoor Raza Mirza, MD

Nordic Society of Gynaecological
Oncology
Dept. of Oncology, Copenhagen
University Hospital
Blegdamsvej 9
2100 Copenhagen, Denmark

Philippe Morice, MD

Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France

Shani Paluch-Shimon, MD

Hadassah Medical Center
Breast Oncology
Kiryat Hadassah
Jerusalem, Jerusalem 91120, IL

Stefan Paepke, MD

Klinikum rechts der Isar
der TU München
Ismaninger Straße 22
81675 Munich, Germany

Max Parmar, MD

MRC Clinical Trials Unit at UCL
90 High Holborn
WC1V 6LJ London, United Kingdom

Melissa Phillips, MD

St Bartholomew's Hospital
W Smithfield
London EC1A 7BE, United Kingdom

Mattea Reinisch, MD

Essen-Mitte Evangelical Hospitals,
HuysSENS Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany

Hope S. Rugo, MD

University of California San
Francisco, UCSF Helen Diller Family
Comprehensive Cancer Center
1450 3rd St., San Francisco
CA 94158 California, USA

Peter Schmid, MD

Charterhouse Square Campus
Charterhouse Square
London EC1M 5PZ, United Kingdom

Jörg Schilling, MD

Specialized oncological practice
Woennichstr. 64
10317 Berlin

David SP Tan, MD

Cancer Science Institute (CSI)
14 Medical Dr
12–01 Centre for Translational
Medicine
117599 Singapore

Marc Thill, MD

AGAPLESION MARKUS HOSPITAL
Wilhelm-Epstein-Straße 4
60431 Frankfurt am Main, Germany

Petra Voiß, MD

Essen-Mitte Evangelical Hospitals
HuysSENS Foundation
Essen-Huttrop
Clinic for Gynecology and
Gynecologic Oncology
Henricistr. 92
45136 Essen, Germany


Rachel Würstlein, MD

Breast Center and CCC Munich
Department of Gynecology and
Obstetrics, University Hospital
Munich, LMU Munich
Marchioninstr. 15
81377 Munich, Germany

Oliver Zivanovic, MD

Medical Director of the Clinic
for Gynaecology and Obstetrics
at the UKHD
University Clinic Heidelberg
Im Neuenheimer Feld 672
69120 Heidelberg, Germany

Room Plan
Ground Floor



Important Deadlines

Abstract submission deadline:	May 13, 2024 (12:00 pm CEST)
Late breaking abstract submission:	June 3, 2024 – June 17, 2024 (12:00 pm CEST)
Notification of acceptance of submitted abstracts:	June 5, 2024

Abstract Guidelines

Abstracts may be submitted online via the [congress website](#).

Abstracts submitted by e-mail will not be accepted.

Abstracts must be received by the **announced deadline**. Abstracts received after the deadline will not be considered.

The title should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title. The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).

Please indicate the topic from the abstract **topics** list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.

Encore abstracts will be accepted unless they have been published in scientific journals.

Please structure the abstract as follows:

- › **Introduction & Objectives:** Describe the background and the purpose of the study
- › **Materials & Methods:** Describe the material and methods used to design the study
- › **Results:** Describe your results in a logical sequence
- › **Conclusions:** Emphasize new and important aspects of the study and conclusions that are drawn from them

The text shall not exceed 350 words including spaces (excluding title, authors bibliography and key words). The submission program will automatically calculate the number of characters in your abstract and will not allow submissions that exceed the maximum number of characters.

It is acceptable to include up to two **tables, graphics, or images (jpg, jpeg, png, gif format, maximum size 2 MB in total)** as part of the abstract.

All abstracts must be submitted and presented in clear **English** with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.

Please use generic names. **The use of commercial drug names, brands and registered trademarks are strictly prohibited.** Drugs should be referred to by the active substance or pharmacological designation.

No mention of pharmaceutical company names should be included in the abstract.

Abstract Topics

BREAST CANCER

- › Biomarkers and translational research and precision medicine
- › Early breast cancer: Adjuvant therapy
- › Early breast cancer: Neoadjuvant therapy
- › Early breast cancer: Surgery and radiotherapy
- › Early detection, hereditary breast cancer and prevention
- › Metastatic breast cancer
- › Supportive care and survivorship
- › Miscellaneous

GYNAE-ONCOLOGY

- › Cervical cancer
- › Endometrial cancer
- › Ovarian cancer
- › Vulva cancer
- › Palliative care
- › Translational research/biomarkers

Patient Privacy / Clinical Photography

Photographs should at all times protect the privacy and identity of the subject. Eyes should be blacked out. The source of the photographs must also be declared if not the property of the presenter. This is to prevent the use of photographic material without permission.

Oral Presentations

Selected abstracts will be chosen for an oral presentation during the oral communications sessions. The presenting author does not have to be the first author.

Poster Presentation

Abstracts selected for poster will be presented as printed Posters during the congress.

Publication

All accepted abstracts will be published in the digital Book of Abstracts which will be available for download on the congress website from July 5th, 2024 onwards.

Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the program.



CALL FOR ABSTRACTS

Abstract AWARDS

The GAWC is pleased to offer the following awards for abstracts submitted for the following categories:

Mini Oral Presentations: Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives. The 3 best abstracts will be selected to be presented during the oral communication session on July 6, 2024, at 11:45.

Poster Awards: Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work. The 6 best Posters on display will be awarded with 500 € each and a free registration to the next Congress. All prize-winning abstracts will be selected by the Poster & Oral Communication Committee. Further information on when the prizes will be awarded will follow.

Abstract Submission

Abstracts can only be submitted online by the Abstract Submission Portal on the event website; submission by e-mail will not be accepted.

SCHOLARSHIPS

Like last year, we would like to invite doctors and students from abroad to participate in the event in Munich. For this purpose, we have set up a Scholarship Fund to support a limited number of doctors and students with their travel expenses.

Each accepted applicant will receive a scholarship of 300,00 EURO in case of successful participation on-site.

The Scholarship only applies to face-to-face attendance. A virtual attendance will not be supported.

We are looking forward to your application!



global-academy-of-womens-cancer.org/scholarships

CME Credits

An application will be made.

Congress Date

July 5th–July 6th, 2024

Congress Organization



Gesellschaft für medizinische Projekte mbH



Project Manager:

Mrs. Beatrice Schröder

E-Mail: event@medconcept.org

Friedenstr. 58

15366 Neuenhagen bei Berlin, Germany

Phone: +49 (0)3342 42689-13

Fax: +49 (0)3342 42689-40

E-Mail: info@medconcept.org

Internet: www.medconcept.org

Congress Website

<http://www.global-academy-of-womens-cancer.org>

Congress Venue

HILTON MUNICH PARK

Am Tucherpark 7

80538 Munich, Germany

Phone: +49 (0)89 3845 0

Fax: +49 (0)89 3845 2588

E-Mail: info.munich@hilton.com

www.munich-park.hilton.com



GENERAL INFORMATION

Exhibition

A commercial exhibition will be held at the congress venue, close to the main meeting room.

Exhibition Opening Hours

Friday, July 5, 2024: 11:00–17:00

Saturday, July 6, 2024: 08:00–17:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

The registration desk is situated at the ground floor of the Hilton Hotel to the right of the reception and in front of the meeting area entrance.

Registration Desk Opening Hours

Friday, July 5, 2024 08:00–19:00

Saturday, July 6, 2024 07:30–17:30

SPONSORS

Platinum



Gold



Bronze



Platinum 130,000 EURO
Gold 95,000 EURO
Silver 65,000 EURO
Bronze 40,000 Euro



IMPORTANT INFORMATION

Congress WIFI

Free WIFI service will be available to all delegates within the Hilton Hotel Munich Park.

Network Name: GAWC

Network password: 2024

Certificate of Attendances

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

